If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIdox Group Regulatory News (IDOX)

  • There is currently no data for IDOX

Year End Trading Update

22 Nov 2023 07:00

RNS Number : 2040U
IDOX PLC
22 November 2023
 

22 November 2023

Idox plc

('Idox', the 'Group' or the 'Company')

Year End Trading Update

A resilient performance in line with expectations

 

Idox plc (AIM: IDOX), a leading supplier of specialist information management software and Geospatial data solutions to the public and asset intensive sectors, today issues a trading update for its financial year ended 31 October 2023 ('FY23').

 

Group trading performance

 

Building on the significant progress the Group has made over the past few years, we are pleased to report Idox has again delivered a resilient performance in line with expectations for FY23 despite the backdrop of continued geo-political and economic uncertainty. We have continued to make good progress towards a number of our medium-term strategic goals, placing the Group on a firm footing for FY24 and beyond.

 

The Group delivered a record order intake of over £82m in FY23, an increase of c.11% on the prior year, reflecting our high-quality customer base and strong market positions.

 

The Board expects to report (subject to external audit) revenue and profit in line with expectations; revenue is expected to be up c.11% to c.£73m, with recurring revenue up c.8% over the period to c.£44m, delivering a c.9% increase in full year adjusted EBITDA to c.£24.5m and a robust adjusted EBITDA margin of c.34% (FY22: 34%).

 

Net debt at 31 October 2023 was £14.7m, including the initial cash consideration of £14.8m paid for Emapsite.com Limited ('Emapsite') as announced on 21 August 2023 (FY22: net debt of £6.7m). In September 2023 the Group completed the refinancing of its lending facilities to a new £75m revolving credit facility and a £45m accordion, a significant increase on the previous facilities which consisted of a revolving credit facility of £35m and £10m accordion, respectively. The new facilities, which are on improved terms, are for a three-year period with two extension options of one year each. The new facilities are provided by the Group's existing syndicate of banks: HSBC Innovation, NatWest and Santander.

 

The integration of Emapsite is underway and will enhance the Group's data capabilities whilst adding significant scale to our Geospatial offering. The Group continues to evaluate a number of further acquisition opportunities, remaining focussed on ensuring strategic alignment at appropriate valuations.

 

We have started FY24 with good levels of visibility - strong recurring revenue, a solid order book and a healthy order pipeline supported by a strengthened financial platform. As a result, our expectations for FY24 remain unchanged, notwithstanding the current macro-environment.

 

David Meaden, Chief Executive Officer of Idox commented:

 

"We are pleased to deliver another solid performance including double-digit revenue growth despite a challenging geo-political and economic backdrop. Our recurring revenue and order intake are both up on the prior year and this provides a solid foundation as we start the new financial year.

 

We are very pleased with the acquisition of Emapsite which adds significant scale and expertise to our existing Geospatial data capabilities. We are excited by the growth opportunities available in this sector, adding to our existing market leading public software capabilities.

 We were delighted to complete a refinancing in the period. The new and increased facilities, which are on improved terms, support our strategic M&A ambitions supplementing our organic growth strategy. Despite the challenging headwinds, our resilient business model allows us to look forward with confidence."

 

 

Notice of results

 

The Group expects to report its FY23 results in late January 2024. Management intends to host a results webinar on the day. Please contact MHP to register your interest.

 

 

Definitions

 

Adjusted EBITDA is defined as earnings before amortisation, depreciation, restructuring, acquisition costs, impairment, financing costs and share option costs.

 

Net debt is defined as the aggregation of cash, bank borrowings and long-term bond.

 

 

For further information please contact:

 

Idox plc

Chris Stone, Non-Executive Chairman

David Meaden, Chief Executive Officer

Anoop Kang, Chief Financial Officer

 

+44 (0) 870 333 7101

investorrelations@idoxgroup.com

Peel Hunt LLP (NOMAD and Broker)

Paul Gillam

Michael Burke

James Smith

 

+44 (0) 20 7418 8900

MHP

Reg Hoare

Ollie Hoare

Matthew Taylor

 

+ 44 (0) 20 3128 8100

idox@mhpgroup.com

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUARRROSUAUUA
Date   Source Headline
31st Mar 20257:00 amRNS2025 AGM Trading update
18th Mar 20259:11 amRNSHolding(s) in Company
17th Mar 20257:00 amRNSEstablishment of EBT and Total Voting Rights
13th Mar 202510:48 amRNSHolding(s) in Company
10th Mar 20253:25 pmRNSHolding(s) in Company
7th Mar 20252:39 pmRNSDirector/PDMR Shareholding
4th Mar 20257:00 amRNSPosting of Annual Report and Notice of AGM
24th Feb 20252:36 pmRNSHolding(s) in Company
24th Feb 20257:01 amRNSHolding(s) in Company
24th Feb 20257:00 amRNSHolding(s) in Company
19th Feb 20257:00 amRNSCorrection of payment date for dividend
10th Feb 20257:00 amRNSAppointment of Senior Independent Director
28th Jan 20257:00 amRNSFinal Results
14th Jan 20257:00 amRNSNotice of Final Results
6th Jan 20257:00 amRNS-RIdox Secures Election Services Contract in Malta
20th Dec 202410:43 amRNSHolding(s) in Company
26th Nov 20247:00 amRNSFull Year 2024 Trading Update
13th Nov 202411:55 amRNSHolding(s) in Company
12th Nov 202410:09 amRNSHolding(s) in Company
28th Oct 20244:49 pmRNSHolding(s) in Company
25th Oct 20247:16 amRNSDirectorate Change
27th Sep 20243:26 pmRNSHolding(s) in Company
25th Sep 20244:28 pmRNSHolding(s) in Company
23rd Sep 20244:00 pmRNSHolding(s) in Company
2nd Sep 20243:42 pmRNSHolding(s) in Company
21st Aug 20245:30 pmRNSExercise of Share Options & Total Voting Rights
7th Aug 20245:20 pmRNSHolding(s) in Company
6th Aug 20242:51 pmRNSHolding(s) in Company
29th Jul 20247:00 amRNSDirector Appointment
11th Jun 20247:00 amRNSHalf Year Results
6th Jun 20247:00 amRNSExercise of Share Options & Total Voting Rights
24th May 20243:06 pmRNSHolding(s) in Company
22nd May 20247:00 amRNSHalf Year 2024 Trading Update
9th May 20247:00 amRNSIssue and Allotment of Consideration Shares
24th Apr 20247:00 amRNSReplacement: Total Voting Rights
17th Apr 202412:43 pmRNSTotal Voting Rights
28th Mar 20245:22 pmRNSHolding(s) in Company
28th Mar 202412:37 pmRNSDirector/PDMR Shareholding
28th Mar 202411:21 amRNSResult of AGM
28th Mar 20247:00 amRNSAGM Trading update
22nd Mar 20245:42 pmRNSDirector/PDMR Shareholding
18th Mar 20247:00 amRNSTotal Voting Rights
11th Mar 20248:40 amRNSHolding(s) in Company
8th Mar 20247:00 amRNSDirector/PDMR Shareholding
5th Mar 20245:12 pmRNSPosting of Annual Report and Notice of AGM
14th Feb 20241:39 pmRNSHolding(s) in Company
9th Feb 20247:00 amRNSExercise of Share Options & Total Voting Rights
25th Jan 20247:00 amRNSFinal Results
18th Jan 202412:35 pmRNSNotice of Final Results
17th Jan 20247:00 amRNSExercise of Share Options & Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.